MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z
  • Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?

    N. Dadphan, O. Jitkritsadakul, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

  • Objective and quantifiable assessment of sleep in patients with Parkinson’s disease using a wearable sensor

    A. Mirelman, I. Hilell, N. Omer, A. Thaler, M. Kestenbaum, O. Assais, A. Orr-Urtreger, M. Brys, J. Cedarbaum, J. Hausdorff, N. Giladi (Tel Aviv, Israel)

  • Objective assessment of Parkinson’s disease motor symptoms during leg agility test using motion sensors

    S. Aghanavesi, M. Memedi, M. Senek, D. Nyholm, F. Bergquist (Borlange, Sweden)

  • Objective Data in Parkinson’s Disease: A description of over 20,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG)

    P. Lynch, R. Pahwa, F. Bergquist, M. Horne (Minnetonka, MN, USA)

  • Objective intestinal dysfunction in REM sleep behaviour disorder

    K. Knudsen, T. Fedorova, A. Hansen, M. Sommerauer, AM. Haase, M. Otto, K. Svendsen, K. Ostergaard, K. Krogh, P. Borghammer (Aarhus, Denmark)

  • Objective Measurement in Routine Care of People with Parkinson’s Disease Improves Outcomes

    M. Horne, P. Farzanehfar, H. Woodrow, M. Braybrook, S. McGregor, A. Evans, F. Nicklason (Parkville, Australia)

  • Objective Measures of Ataxic Gait Using Wearable Inertial Sensors

    M. El-Gohary, L. Horak, C. Gomez (Portland, OR, USA)

  • Objective monitoring of drug response in early PD patients using remote, at-home typing data through machine learning analysis

    M. Matarazzo, T. Arroyo-Gallego, P. Montero Escribano, V. Puertas-Martín, I. Butterworth, C. S. Mendoza, MJ. Ledesma-Carbayo, MJ. Catalán, JA. Molina-Arjona, F. Bermejo-Pareja, JC. Martínez Castrillo, L. López-Manzanares, A. Alonso-Cánovas, J. Herreros-Rodríguez, I. Obeso, P. Martínez Martín, JC. Martínez-Ávila, A. Gómez de-la-Cámara, M. Gray, JA. Obeso, L. Giancardo, Á. Sánchez-Ferro (Vancouver, BC, Canada)

  • Objective Predictors of ‘Early Tolerance’ to Ventral Intermediate nucleus of thalamus DBS In Essential Tremor Patients

    S. Merchant, S. Kuo, S. Pullman, B. Ford (Bethesda, MD, USA)

  • Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

    K. Chaudhuri, A. Sauerbier, J. Ferreira, F. Stocchi, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

  • Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience

    A. Ceballos-Baumann, K. Eggert, J. Ferreira, W. Poewe, O. Rascol, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Munich, Germany)

  • Ocular flutter, generalized myoclonus and ataxia syndrome associated with Human Immunodeficiency Virus: A case report

    K. Tan, GB. Eow, A.A. Augustine (George Town, Malaysia)

  • Ocular motor function in stiff person syndrome – Role of GABA and beyond

    F. Wang, L. Neilson, H. Wang, G. Wilmot, A. Shaikh (Cleveland, OH, USA)

  • Oculomotor Behavior in Healthy Caribbean: Does it reflect an increased vulnerability to degenerative Parkinsonism?

    A. Lannuzel, A. Lackmy, B. Tressières, R. Edragas, V. Pélonde-Erimée, C. Bonnet, S. Rivaud-Péchoux, E. Roze, B. Gaymard (Pointe-à-Pitre, Guadeloupe)

  • ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

    J. Tuunainen, J. Ellmén, M. Vahteristo, A. Holopainen, D. Strugala (Espoo, Finland)

  • Odor identification in PD patients and controls in Estonian cohort

    I. Kalju, T. Toomsoo, K. Vender (Tallinn, Estonia)

  • Off-painfull state in Parkinson’s disease patients: A redflag of complulsive behavior. Data from a PET-FDG study

    G. Albani, A. Cistaro, P. Fania, S. Margotti, V. Arena, A. Mauro (Verbania, Italy)

  • Olfactory dysfunction predicting cognition

    X. Yu (Cleveland, OH, USA)

  • Olfactory dysfunction, sleep disturbances, neuronal loss, and regional brain atrophy in an inducible mouse model of Alpha-Synucleinopathy

    E. Brison, S. Zehntner, A. Zijdenbos, K. Luk, B. Bedell (Montreal, QC, Canada)

  • Olfactory Hallucinations as a Non-motor sign of Parkinson’s disease – A cross-sectional study amongst patients in a tertiary movement center

    S. Chandra, M. Schiess, R. Mehanna (Houston, TX, USA)

  • Olfactory impairment correlates strongly with limbic blood flow in patients with Parkinson’s disease

    K. Ohta, T. Nakajima (Niigata, Japan)

  • Olfactory testing in Parkinson plus syndromes

    O. Abdukarimov, F. Akhmedova (Tashkent, Uzbekistan)

  • Oligosymptomatic Fahr’s syndrome (2 clinical cases)

    Y. Solodovnikova (Odessa, Ukraine)

  • On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios

    S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)

  • On the hunt for a link between genetically confirmed Huntington’s disease and Amyotrophic Lateral Sclerosis

    L. Williams, K. O'Connell, D. Burke, J. Cryan, D. McCabe (Dublin, Ireland)

  • Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease

    C. Kwan, I. Frouni, D. Bédard, A. Hamadjida, P. Huot (Montreal, QC, Canada)

  • Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis

    T. Dam, L. Zhang, I. Qureshi, M. Grundman, G. Tirucherai, C. Bechtold, M. Ahlijanian, L. Golbe, L. Honig, S. Isaacson, M. Grossman, N. McFarland, I. Litvan, D. Geldmacher, T. Xie, Y. Bordelon, P. Tuite, P. O’Suilleabhain, T. Zesiewicz, B. Han, A. Boxer (Cambridge, MA, USA)

  • Open-label pilot trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)

    D. Hall, E. Robertson, M. Leehey, A. McAsey, B. Ouyang, E. Berry-Kravis, J. O'Keefe (Chicago, IL, USA)

  • Opposite effects of dopamine on specific NoGo perfomance in young and late onset Parkinson’s disease and the relationship to nigrostriatal degeneration

    D. Kübler, H. Schroll, U. Scheller, R. Buchert, A. Kühn (Berlin, Germany)

  • Optimization of deep brain stimulation in STN among patients with Parkinson’s disease using a novel EEG-based tool

    D. Sand, Z. Peremen, D. Haor, S. Israeli-Korn, D. Arkadir, M. Abu Snineh, Z. Israel, S. Hassin-Baer, R. Eitan, H. Bergman, A. Geva (Jerusalem and Herzlia, Israel)

  • Optimization of Region of Interest Analysis of the Superior Colliculus for Improved Activation Detection in Cervical Dystonia

    S. Narasimham, E. McGovern, O. Killian, R. Beck, M. Farrell, S. O’Riordan, M. Hutchinson, R. Reilly (Dublin, Ireland)

  • Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD)

    A. Thaker, K. Reddy, J. Thompson, P. David-Gerecht, A. Abosch, D. Kern (Aurora, CO, USA)

  • Optimizing the Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) outcome in Parkinson’s disease patient with interleaving stimulation

    C. Lau, C. Zhu, D. Chan, K. Ma, A. Chan, J. Yeung, V. Mok, W. Poon (Hong Kong)

  • Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

    P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

  • Oral treatment with sphingosine-1-phosphate receptors modulator prevents Parkinson symptoms concomitantly to reduced brain inflammation in MPTP mouse models

    M. Cyr, E. Pépin, G. Massicotte (Trois-Rivieres, QC, Canada)

  • Orthostatic tremor does not stop during walking: Is this a stop sign for research?

    W. Hu, E. Opri, Z. Jabarkheel, A. Schmitt, C. Hass, C. Hess, M. Okun, A. Wagle Shukla (Gainesville, FL, USA)

  • Outcomes of a Prospective, Multi-center International Registry of Deep Brain Stimulation for Parkinson’s Disease

    G. Deuschl, R. Jain, H. Scholtes, A. Wang, M. Barbe, S. Paschen, A. Andrea Kühn, M. Pötter-Nerger, J. Volkmann, J. Vesper (Kiel, Germany)

  • Outcomes of elective orthopedic surgery in Parkinson’s disease – a Nationwide study

    M. Fullard, D. Thibault, A. Willis (Philadelphia, PA, USA)

Jump to:  View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley